Aarti Drugs Limited Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2016
May 05, 2016 at 06:37 am EDT
Share
Aarti Drugs Limited reported audited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2016. For the quarter, on standalone basis, net sales/income from operations were INR 2,969.5 million compared with INR 2,776.1 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 346.6 million compared with INR 348.2 million for the same period last year. Profit from ordinary activities before tax was INR 234.1 million compared with INR 250.6 million for the same period last year. Net profit for the period was INR 171.1 million or INR 7.07 basic and diluted per share as compared to INR 188.6 million or INR 7.79 basic and diluted per share for the same period last year.
For the year, on standalone basis, net sales/income from operations were INR 10,707.3 million compared with INR 10,844.8 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 1,361.2 million compared with INR 1,382.9 million for the same period last year. Profit from ordinary activities before tax was INR 928.4 million compared with INR 1,000.6 million for the same period last year. Net profit for the period was INR 662.9 million or INR 27.37 basic and diluted per share as compared to INR 776.0 million or INR 32.04 basic and diluted per share for the same period last year.
For the quarter, on consolidated basis, net sales/income from operations were INR 3,139.7 million compared with INR 2,649.9 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 364.0 million compared with INR 340.2 million for the same period last year. Profit from ordinary activities before tax was INR 248.9 million compared with INR 227.8 million for the same period last year. Net profit for the period was INR 185.9 million or INR 7.68 basic and diluted per share as compared to INR 170.3 million or INR 7.03 and diluted per share for the same period last year.
For the year, on consolidated basis, net sales/income from operations were INR 11,348.8 million compared with INR 10,942.7 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 1,391.6 million compared with INR 1,380.0 million for the same period last year. Profit from ordinary activities before tax was INR 952.7 million compared with INR 997.2 million for the same period last year. Net profit for the period was INR 687.2 million or INR 28.38 basic and diluted per share as compared to INR 772.5 million or INR 31.90 basic and diluted per share for the same period last year. Consolidated EBITDA was INR 1,756.9 million, up by 3.55%.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
